# An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

> **NCT01454531** · PHASE2,PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 199 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis

## Interventions

- **DRUG:** AVANZ Phleum pratense

## Key facts

- **NCT ID:** NCT01454531
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-04
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454531, "An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01454531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*